Skip to main
AIM

AIM Stock Forecast & Price Target

AIM Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AIM ImmunoTech is a promising early-stage biotech company with a strong balance sheet and multiple shots on goal in the form of 13 active clinical trials. The company's primary focus on developing Ampligen for the treatment of late-stage pancreatic cancer is a smart decision, given the success of trials and the high mortality rates of the disease. Upcoming positive clinical data and progress on pivotal studies have the potential to be major catalysts for the stock. However, investors should be aware of the risks associated with biotech investments, including regulatory approval and commercialization challenges.

Bears say

AIM ImmunoTech is currently facing significant financial and regulatory risks which could hinder the future development and commercialization of its drug candidates. With a long development road ahead and uncertainties surrounding regulatory approvals and commercialization, the potential market for AIM's drugs may not fully materialize, making its stock a high-risk investment. Additionally, while the company has multiple clinical trials underway, its success is not guaranteed as there is intense competition in the biotech industry and changing macroeconomic factors may impact investor sentiment for investing in this sector.

AIM has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AIM ImmunoTech Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AIM ImmunoTech Inc (AIM) Forecast

Analysts have given AIM a Strong Buy based on their latest research and market trends.

According to 1 analysts, AIM has a Strong Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AIM ImmunoTech Inc (AIM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.